Choline Source, Gut Microbiota and Trimethylamine-N-oxide Response

Overview

The purpose of this research is to determine the production of trimethylamine-N-oxide (TMAO) from different forms of choline and whether this response is modified by the gut microbiota composition.

Full Title of Study: “Effect of Choline Source and Gut Microbiota Composition on Trimethylamine-N-oxide Response in Humans”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: June 16, 2018

Detailed Description

The overall goal of this research is to identify dietary and physiological factors contributing to elevated levels of trimethylamine-N-oxide (TMAO), a choline-derived gut-microbiome-dependent metabolite that has been identified to increase cardiovascular disease risk. Our recent findings indicate that the gut microbiome may account for variations in TMAO levels, whereby those with a greater enrichment of Firmicutes to Bacteroidetes had elevated TMAO response to dietary precursor intake. However, the interaction between choline intake and gut microbiota composition as a determinant of interindividual variations in TMAO response has not been investigated. This study sought to i) compare plasma and urinary TMAO response after acute challenge containing different forms of choline; and ii) to determine the association between differences in TMAO response with differences in gut microbiota composition. To accomplish these objectives, a randomized, controlled cross-over study was conducted in healthy participants (n=41). The study incorporated three arms comprised of study meals containing (i) 600 mg choline as choline bitartrate; (ii) 600 mg choline as phosphatidylcholine; or (iii) no choline. Each meal was served with a bagel with margarine-butter spread and one cup of water, administered in a single day and separated by a 1-week washout period. Baseline blood sample was obtained by a phlebotomist using a standard venipuncture procedure, and participants collected their baseline urine sample. They also turned in a one-time self-collected baseline stool sample. Following the consumption of the study meal, serial blood samples were collected at 30 min and 1, 2, 4 and 6 h, and urine samples collected throughout the 6 h study period. At 4.5 h, participants were provided a fixed fruit snack (i.e., 2 single serving prepackaged applesauce) and water.

Interventions

  • Other: Water-soluble choline
    • 600 mg choline as choline bitartrate
  • Other: Fat-soluble choline
    • 600 mg choline as phosphatidylcholine
  • Other: No choline control
    • No choline

Arms, Groups and Cohorts

  • Experimental: Water-soluble choline
    • A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as choline bitartrate; served with a bagel with margarine-butter spread and one cup of water.
  • Experimental: Fat-soluble choline
    • A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as phosphatidylcholine; served with a bagel with margarine-butter spread and one cup of water.
  • Active Comparator: No choline
    • A breakfast meal consisting of 1 cup of tomato soup containing no choline; served with a bagel with margarine-butter spread and one cup of water.

Clinical Trial Outcome Measures

Primary Measures

  • TMAO metabolite concentration change
    • Time Frame: Blood: study baseline, 30 minutes and 1 hour, 2 hours, 4 hours and 6 hours
    • Plasma TMAO metabolite response
  • TMAO metabolite concentration change
    • Time Frame: Urine: study baseline, pooled 6 hours study period
    • Urinary TMAO metabolite response
  • Gut microbiome profile
    • Time Frame: Stool: one-time baseline
    • 16S rRNA

Secondary Measures

  • One-carbon metabolite concentration change
    • Time Frame: Blood: study baseline, 30 minutes and 1 hour, 2 hours, 4 hours and 6 hours
    • Plasma choline metabolite response
  • Phosphatidylcholine concentration change
    • Time Frame: Blood: study baseline, 30 minutes and 1 hour, 2 hours, 4 hours and 6 hours
    • Plasma phosphatidylcholine response
  • One-carbon metabolite concentration change
    • Time Frame: Urine: study baseline, pooled 6 hours study period
    • Urinary choline metabolite response
  • Inflammation and cardiovascular disease risk marker concentration change
    • Time Frame: Blood: study baseline to 6 hours
    • Plasma TNF-α and IL-6
  • Flavin monooxygenase 3 (FMO3) 472 G>A genotype variant
    • Time Frame: Blood: study baseline
    • Genetic polymorphism

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy men and women of any race or ethnicity – Age 21-50 y – BMI 20-24.9 kg/m2 or BMI 30-39.9 kg/m2 Exclusion Criteria:

  • Age > 50 y – BMI outside of the normal-weight or obese range (BMI < 20 kg/m2; BMI 25-29.9 kg/m2; or BMI > or = 40 kg/m2) – Pregnant or planning to become pregnant during the course of the study; currently breastfeeding (females) – Vegetarians – Smokers or recreational drug users – Individuals with gastrointestinal diseases or complaints, chronic illnesses or other metabolic diseases (including trimethylaminuria) – Individuals who have taken antibiotics within the past 2 months – Individuals who are not willing to discontinue pre- and probiotics and dietary supplements for the time leading up to 2 months before the study and during the study

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Utah State University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Clara E Cho, PhD, Principal Investigator, Utah State University

References

Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013 Apr 25;368(17):1575-84. doi: 10.1056/NEJMoa1109400.

Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011 Apr 7;472(7341):57-63. doi: 10.1038/nature09922.

Cho CE, Taesuwan S, Malysheva OV, Bender E, Tulchinsky NF, Yan J, Sutter JL, Caudill MA. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: A randomized controlled trial. Mol Nutr Food Res. 2017 Jan;61(1). doi: 10.1002/mnfr.201600324. Epub 2016 Aug 3.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.